Icosavax releases phase 1 results for bivalent RSV/metapneumovirus vaccine
Manjurul/iStock via Getty Images
- Interim phase 1 results of Icosavax's (NASDAQ:ICVX) IVX-A12, a bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), showed a robust immune response and was well tolerated.
- IVX-A12 is composed of IVX-121, a RSV prefusion F protein VLP vaccine candidate, and IVX-241, a hMPV prefusion F protein VLP vaccine candidate.
- Data showed that robust IVX-A12 led to a strong immune response against both viruses at day 28. In addition, adverse events were generally mild or moderate.
- Icosavax (ICVX) plans to begin a phase 2 immunogenicity trial mid year, followed by an hMPV human challenge study as a proof-of-concept efficacy study.
- Separately, the company said a $67.8M registered direct offering would extend its cash runway into 2H 2025.
- Seeking Alpha's Quant Rating upgraded the stock to buy from hold on May 11.